These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 10359368)

  • 21. Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant. Lyme Disease Vaccine Study Group.
    Steere AC; Sikand VK; Meurice F; Parenti DL; Fikrig E; Schoen RT; Nowakowski J; Schmid CH; Laukamp S; Buscarino C; Krause DS
    N Engl J Med; 1998 Jul; 339(4):209-15. PubMed ID: 9673298
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The outer surface lipoprotein A of Borrelia burgdorferi provides direct and indirect augmenting/co-stimulatory signals for the activation of CD4+ and CD8+ T cells.
    Simon MM; Nerz G; Kramer MD; Hurtenbach U; Schaible UE; Wallich R
    Immunol Lett; 1995 Jun; 46(3):137-42. PubMed ID: 7590937
    [No Abstract]   [Full Text] [Related]  

  • 23. Importance of protective borreliacidal antibodies in Lyme disease immunity and serodiagnosis.
    Callister SM; Schell RF
    J Infect Dis; 1994 Aug; 170(2):499-500. PubMed ID: 8035047
    [No Abstract]   [Full Text] [Related]  

  • 24. The Lyme disease vaccine: conception, development, and implementation.
    Thanassi WT; Schoen RT
    Ann Intern Med; 2000 Apr; 132(8):661-8. PubMed ID: 10766685
    [TBL] [Abstract][Full Text] [Related]  

  • 25. From the Food and Drug Administration.
    Nightingale SL
    JAMA; 1999 Feb; 281(5):408. PubMed ID: 9952188
    [No Abstract]   [Full Text] [Related]  

  • 26. The complex formation of influenza virus envelope glycoproteins with outer membrane proteins of Neisseria meningitidis or Borrelia burgdorferi.
    Slávik I; Pristasová S; Visacká E; Sláviková K; Matoska J; Toman R; Klockmann U
    Acta Virol; 1993 Dec; 37(6):449-58. PubMed ID: 8010183
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunization with a recombinant subunit OspA vaccine markedly impacts the rate of newly acquired Borrelia burgdorferi infections in client-owned dogs living in a coastal community in Maine, USA.
    Eschner AK; Mugnai K
    Parasit Vectors; 2015 Feb; 8():92. PubMed ID: 25890386
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Studies on OspA: a source of new paradigms in Lyme disease research.
    Philipp MT
    Trends Microbiol; 1998 Feb; 6(2):44-7. PubMed ID: 9507636
    [No Abstract]   [Full Text] [Related]  

  • 29. Prospects for a vaccine to prevent Lyme disease in humans.
    Wormser GP
    Clin Infect Dis; 1995 Nov; 21(5):1267-74. PubMed ID: 8589153
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A recombinant vaccine for Lyme disease.
    Wallich R; Kramer MD; Simon MM
    Behring Inst Mitt; 1994 Dec; (95):106-8. PubMed ID: 7755503
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characterization of recombinant OspA in two different Borrelia vaccines with respect to immunological response and its relationship to functional parameters.
    Grosenbaugh DA; De Luca K; Durand PY; Feilmeier B; DeWitt K; Sigoillot-Claude C; Sajous ML; Day MJ; David F
    BMC Vet Res; 2018 Oct; 14(1):312. PubMed ID: 30326885
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Protection against antigenically variable Borrelia burgdorferi conferred by recombinant vaccines.
    Telford SR; Fikrig E; Barthold SW; Brunet LR; Spielman A; Flavell RA
    J Exp Med; 1993 Aug; 178(2):755-8. PubMed ID: 8340764
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Keeping Lyme disease at bay. An integrated approach to prevention.
    Wade CF
    Am J Nurs; 2000 Jul; 100(7):26-31; quiz 32. PubMed ID: 10914066
    [No Abstract]   [Full Text] [Related]  

  • 34. Crystallization and preliminary X-ray analysis of Borrelia burgdorferi outer surface protein A (OspA) complexed with a murine monoclonal antibody Fab fragment.
    Li H; Lawson CL
    J Struct Biol; 1995; 115(3):335-7. PubMed ID: 8573475
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Systemic and mucosal immunity induced by BCG vector expressing outer-surface protein A of Borrelia burgdorferi.
    Langermann S; Palaszynski S; Sadziene A; Stover CK; Koenig S
    Nature; 1994 Dec; 372(6506):552-5. PubMed ID: 7990928
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunogenicity of a recombinant Borrelia burgdorferi outer surface protein A vaccine against Lyme disease in children.
    Feder HM; Beran J; Van Hoecke C; Abraham B; De Clercq N; Buscarino C; Parenti DL
    J Pediatr; 1999 Nov; 135(5):575-9. PubMed ID: 10547245
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characterization of canine humoral immune responses to outer surface protein subunit vaccines and to natural infection by Lyme disease spirochetes.
    Ma J; Bulger PA; Dante S; Davis DR; Perilli-Palmer B; Coughlin RT
    J Infect Dis; 1995 Apr; 171(4):909-15. PubMed ID: 7706819
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Activation of human monocytic cells by Borrelia burgdorferi and Treponema pallidum is facilitated by CD14 and correlates with surface exposure of spirochetal lipoproteins.
    Sellati TJ; Bouis DA; Caimano MJ; Feulner JA; Ayers C; Lien E; Radolf JD
    J Immunol; 1999 Aug; 163(4):2049-56. PubMed ID: 10438943
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of Borrelia burgdorferi-tick interactions in vivo by outer surface protein A antibody.
    Pal U; Montgomery RR; Lusitani D; Voet P; Weynants V; Malawista SE; Lobet Y; Fikrig E
    J Immunol; 2001 Jun; 166(12):7398-403. PubMed ID: 11390491
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of immunization with recombinant OspA on serologic tests for Lyme borreliosis.
    Fawcett PT; Rose CD; Budd SM; Gibney KM
    Clin Diagn Lab Immunol; 2001 Jan; 8(1):79-84. PubMed ID: 11139199
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.